Overview
Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome (Orphanet code 261559) is an obsolete disease entry that was previously used to describe cases of blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) attributed specifically to chromosomal rearrangements involving the 3q23 region. BPES is a developmental condition primarily affecting the eyelids and surrounding structures, characterized by four major features: blepharophimosis (narrowing of the horizontal eye opening), epicanthus inversus (a skin fold arising from the lower eyelid), ptosis (drooping of the upper eyelids), and telecanthus (increased distance between the inner corners of the eyes). These features are typically present from birth and can impair vision if left untreated. This specific entry has been marked as obsolete in Orphanet, meaning it has been retired and its cases are now classified under the broader BPES entity (Orphanet code 126), which is most commonly caused by mutations or rearrangements involving the FOXL2 gene located at chromosome 3q22.3-q23. BPES is inherited in an autosomal dominant pattern and is subdivided into two types: Type I, which includes premature ovarian insufficiency in females, and Type II, which involves only the eyelid malformations. Management typically involves surgical correction of the ptosis and blepharophimosis, usually performed in early childhood to optimize visual development and prevent amblyopia. Patients with Type I BPES may also require reproductive counseling and hormonal management for ovarian insufficiency.
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
Start the conversation →Latest news about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome
No recent news articles for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome
What is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome?
Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome (Orphanet code 261559) is an obsolete disease entry that was previously used to describe cases of blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) attributed specifically to chromosomal rearrangements involving the 3q23 region. BPES is a developmental condition primarily affecting the eyelids and surrounding structures, characterized by four major features: blepharophimosis (narrowing of the horizontal eye opening), epicanthus inversus (a skin fold arising from the lower eyelid), ptosis (drooping of the u
How is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome inherited?
OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome typically begin?
Typical onset of OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome is neonatal. Age of onset can vary across affected individuals.